NKTX · Nkarta, Inc.

Nkarta's Q1 2026 results showed a narrowed net loss of $27.8 million compared to $32.0 million in the prior year quarter, driven by lower G&A expenses of $5.9 million versus $12.4 million, while R&D remained stable at $25.0 million. Total operating expenses declined to $30.9 million from $36.6 million year-over-year. The company maintained a strong cash position of $266.7 million as of March 31, 2026, down from $295.1 million at year-end 2025, sufficient to fund operations into 2029 without near-term dilution risk. CEO Paul J. Hastings highlighted patient-centric advancements, including FDA agreement in early April 2026 to amend protocols for Ntrust-1 and Ntrust-2 trials, enabling outpatient dosing in community settings, re-dosing options, elimination of overnight monitoring, and expansion to rheumatoid arthritis patients. Enrollment continues at the 4 billion cell per dose level (12 billion total in three-dose cycle) across autoimmune indications like systemic sclerosis, idiopathic inflammatory myopathy, and others. IRB approvals are secured at multiple sites, broadening access beyond academic centers. Initial clinical data from these trials is anticipated at a medical conference in 2026, representing a key upcoming catalyst for investors.